- Previous Close
1.4400 - Open
1.4000 - Bid --
- Ask --
- Day's Range
1.3000 - 1.3600 - 52 Week Range
1.3000 - 3.8500 - Volume
16,976 - Avg. Volume
12,610 - Market Cap (intraday)
47.038M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8900 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
www.armatapharma.comRecent News: ARMP
View MorePerformance Overview: ARMP
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARMP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARMP
View MoreValuation Measures
Market Cap
47.04M
Enterprise Value
164.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.70%
Return on Equity (ttm)
--
Revenue (ttm)
5.17M
Net Income Avi to Common (ttm)
-18.92M
Diluted EPS (ttm)
-0.8900
Balance Sheet and Cash Flow
Total Cash (mrq)
9.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-29.4M